| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50324-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-123SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-122SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-94154-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-93604-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-11921-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-93606-0.025mg | |||
![Western Blot: TAO Kinase 1 Antibody (TAO1 1.2) [NBP2-50324] - HeLa cells were transfected with Negative control siRNA (Neg) or TAO1 siRNAs to assess the extent of protein depletion](http://images.novusbio.com/fullsize/antibody/NBP2-50324-WBjpg.jpg "<b>Genetic Strategies Validation. </b>Western Blot: TAO Kinase 1 Antibody (TAO1 1.2) [NBP2-50324] - HeLa cells were transfected with Negative control siRNA (Neg) or TAO1 siRNAs to assess the extent of protein depletion")
![Western Blot: PDGFR alpha Antibody (OTI1C10) - Azide and BSA Free [NBP2-73303] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PDGF R alpha.](http://images.novusbio.com/fullsize/PDGFR-alpha-Antibody-OTI1C10-Azide-and-BSA-Free-Western-Blot-NBP2-73303-img0001.jpg "Western Blot: PDGFR alpha Antibody (OTI1C10) - Azide and BSA Free [NBP2-73303] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PDGF R alpha.")
![Western Blot: MAP3K15 Antibody (OTI1G10) - Azide and BSA Free [NBP2-72588] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY MAP3K15.](http://images.novusbio.com/fullsize/MAP3K15-Antibody-OTI1G10-Azide-and-BSA-Free-Western-Blot-NBP2-72588-img0001.jpg "Western Blot: MAP3K15 Antibody (OTI1G10) - Azide and BSA Free [NBP2-72588] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY MAP3K15.")
![Western Blot: VRK1 Antibody (OTI2C9) - Azide and BSA Free [NBP2-74855] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VRK1.](http://images.novusbio.com/fullsize/VRK1-Antibody-OTI2C9-Azide-and-BSA-Free-Western-Blot-NBP2-74855-img0001.jpg "Western Blot: VRK1 Antibody (OTI2C9) - Azide and BSA Free [NBP2-74855] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VRK1.")
![Western Blot: ROR1 Antibody (OTI3D11) - Azide and BSA Free [NBP2-73931] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY ROR1 .](http://images.novusbio.com/fullsize/ROR1-Antibody-OTI3D11-Azide-and-BSA-Free-Western-Blot-NBP2-73931-img0001.jpg "Western Blot: ROR1 Antibody (OTI3D11) - Azide and BSA Free [NBP2-73931] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY ROR1 .")
![Western Blot: PRAK Antibody (OTI5E1) - Azide and BSA Free [NBP2-73594] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRAK.](http://images.novusbio.com/fullsize/PRAK-Antibody-OTI5E1-Azide-and-BSA-Free-Western-Blot-NBP2-73594-img0001.jpg "Western Blot: PRAK Antibody (OTI5E1) - Azide and BSA Free [NBP2-73594] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRAK.")
![Immunohistochemistry: FGFR2 Antibody (7C24) [NB110-94154] - Paraffin kidney and lung sections from LPS treated mice were subjected to IHC using anti FGF-R2 antibody RM0025-7C24](http://images.novusbio.com/fullsize/FGFR2-Antibody-7C24-Immunohistochemistry-NB110-94154-img0001.jpg "Immunohistochemistry: FGFR2 Antibody (7C24) [NB110-94154] - Paraffin kidney and lung sections from LPS treated mice were subjected to IHC using anti FGF-R2 antibody RM0025-7C24")
![Immunohistochemistry: EPH Receptor A4 Antibody (11C13) [NB110-93604] - Paraffin liver and heart sections from LPS treated mice were subjected to IHC using anti EPH Receptor A4 Antibody (11C13)RM-0053-11C13.](http://images.novusbio.com/fullsize/EPH-Receptor-A4-Antibody-11C13-Immunohistochemistry-NB110-93604-img0002.jpg "Immunohistochemistry: EPH Receptor A4 Antibody (11C13) [NB110-93604] - Paraffin liver and heart sections from LPS treated mice were subjected to IHC using anti EPH Receptor A4 Antibody (11C13)RM-0053-11C13.")
![Immunohistochemistry-Paraffin: TGF-beta RI/ALK-5 Antibody (RM0016-3A11) [NBP2-11921] - Parrafin lung and kidney sections from LPS treated mice using anti ALK5 antibody.](http://images.novusbio.com/fullsize/TGF-beta-RI-ALK-5-Antibody-RM0016-3A11-Immunohistochemistry-Paraffin-NBP2-11921-img0002.jpg "Immunohistochemistry-Paraffin: TGF-beta RI/ALK-5 Antibody (RM0016-3A11) [NBP2-11921] - Parrafin lung and kidney sections from LPS treated mice using anti ALK5 antibody.")
![Immunohistochemistry-Paraffin: EphA7 Antibody (6E1) [NB110-93606] - The Kidney tissue samples from the Folic Acid induced kidney injury model were fixed using 4% PFA at 4C for overnight and embeded in paraffin. 4um section was sublected to IHC with NB110-93606](http://images.novusbio.com/fullsize/EphA7-Antibody-6E1-Immunohistochemistry-Paraffin-NB110-93606-img0001.jpg "Immunohistochemistry-Paraffin: EphA7 Antibody (6E1) [NB110-93606] - The Kidney tissue samples from the Folic Acid induced kidney injury model were fixed using 4% PFA at 4C for overnight and embeded in paraffin. 4um section was sublected to IHC with NB110-93606")